Last reviewed 2026-04-22 · How we verify

Anagliptin BID Treatment

JW Pharmaceutical · FDA-approved active Small molecule

Anagliptin BID Treatment is a DPP-4 inhibitor Small molecule drug developed by JW Pharmaceutical. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: Sitagliptin QD Treatment.

Anagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.

Anagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals. Used for Type 2 diabetes mellitus.

At a glance

Generic name	Anagliptin BID Treatment
Also known as	Sitagliptin QD Treatment
Sponsor	JW Pharmaceutical
Drug class	DPP-4 inhibitor
Target	Dipeptidyl peptidase-4 (DPP-4)
Modality	Small molecule
Therapeutic area	Diabetes
Phase	FDA-approved

Mechanism of action

As a DPP-4 inhibitor, anagliptin prevents the degradation of GLP-1 and GIP, incretin hormones that regulate postprandial glucose levels. By extending the half-life of these hormones, anagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release, thereby lowering blood glucose in patients with type 2 diabetes. The BID (twice-daily) dosing regimen optimizes glycemic control throughout the day.

Approved indications

Type 2 diabetes mellitus

Common side effects

Nasopharyngitis
Headache
Hypoglycemia
Upper respiratory tract infection

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Anagliptin BID Treatment CI brief — competitive landscape report
Anagliptin BID Treatment updates RSS · CI watch RSS
JW Pharmaceutical portfolio CI

Frequently asked questions about Anagliptin BID Treatment

What is Anagliptin BID Treatment?

Anagliptin BID Treatment is a DPP-4 inhibitor drug developed by JW Pharmaceutical, indicated for Type 2 diabetes mellitus.

How does Anagliptin BID Treatment work?

Anagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.

What is Anagliptin BID Treatment used for?

Anagliptin BID Treatment is indicated for Type 2 diabetes mellitus.

Who makes Anagliptin BID Treatment?

Anagliptin BID Treatment is developed and marketed by JW Pharmaceutical (see full JW Pharmaceutical pipeline at /company/jw-pharmaceutical).

Is Anagliptin BID Treatment also known as anything else?

Anagliptin BID Treatment is also known as Sitagliptin QD Treatment.

What drug class is Anagliptin BID Treatment in?

Anagliptin BID Treatment belongs to the DPP-4 inhibitor class. See all DPP-4 inhibitor drugs at /class/dpp-4-inhibitor.

What development phase is Anagliptin BID Treatment in?

Anagliptin BID Treatment is FDA-approved (marketed).

What are the side effects of Anagliptin BID Treatment?

Common side effects of Anagliptin BID Treatment include Nasopharyngitis, Headache, Hypoglycemia, Upper respiratory tract infection.

What does Anagliptin BID Treatment target?

Anagliptin BID Treatment targets Dipeptidyl peptidase-4 (DPP-4) and is a DPP-4 inhibitor.

Drug class: All DPP-4 inhibitor drugs
Target: All drugs targeting Dipeptidyl peptidase-4 (DPP-4)
Manufacturer: JW Pharmaceutical — full pipeline
Therapeutic area: All drugs in Diabetes
Indication: Drugs for Type 2 diabetes mellitus
Also known as: Sitagliptin QD Treatment